In Depth 27 Jun 2025 Psychedelics sans side effects: neuroplastogens gain ground …in neuropsychiatry. With its lead candidate in the Investigational New Drug (IND)-enabling stage, the Washington-based startup hopes to head to the clinic to treat depression and PTSD soon. As about… June 27, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2017 UPDATE: Verona sets terms & dials back its IPO goal to a still-hefty €75M …its lead candidate RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The company also announced the dosing of the first patient for its new… April 19, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Aug 2023 Six Toronto-based biotech companies to watch this year …like Deep Genomics having developed a portfolio of candidates, some of which are being evaluated as therapies for central nervous system (CNS)-related disorders, the city’s research and development sector is… August 17, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 5 Sep 2017 The Next Generation of Genetic Medicine: A Review of Epigenetics …that patient stratification is not an option. A German company, 4SC, has taken heed of such findings, combining its lead candidate resminostat with Bayer’s kinase inhibitor, Nexavar (sorafenib). In January,… September 5, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies …Ipsen for the development and commercialization of mesdopetam. IRLAB has generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its… September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2023 Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition …types, and potentially to improve the safety profile of their future gene therapies. Ginkgo Bioworks is also receiving StrideBio’s existing library of capsids, which includes advanced candidates extensively tested in… April 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 First patient receives new immunotherapy drug for HIV in clinical trial …a new class of bispecific protein immunotherapy being developed for the treatment of patients with HIV. IMC-M113V is the second candidate in development using Immunocore’s immune‐mobilising monoclonal T cell receptors… July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2017 Meet these 5 Awesome Biotechs from Barcelona at BIO Europe Spring 2017 …when it licensed its lead candidate, ORY-1001, to Roche. The company’s pipeline candidates target lysine-specific demethylase 1 (LSD1), a histone modifying enzyme that regulates the expression of genes involved in… February 22, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 Bang and the Wart is Gone! Norwegian Peptide Destroys HPV-Infected Cells …treatment of dermatological problems, including cutaneous warts caused by human papillomavirus. It lead candidate, CyPep-H1, uses a new mechanism of action to specifically target and destroy cells infected by the… January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2017 Stem Cell Therapy for Sepsis in Pneumonia advances to Phase II TiGenix has treated the first patient in a new early-stage clinical trial to test its candidate Cx611 as a treatment for sepsis in patients with pneumonia. TiGenix, based in Belgium,… February 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2020 €30M Series A to Fund Spanish Biotech’s Anti-Metastasis Cancer Drug …candidate is already in phase II clinical trials for the treatment of solid tumors. In contrast to Ona’s project, which focuses on fat metabolism, Vigeo’s candidate causes cells to produce… June 17, 2020 - 2 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
In Depth 11 Aug 2025 Zombie biotechs and the mission to make them disappear fast …scrapped the development of its TIGIT inhibitor after it failed a phase 2 clinical trial in May. The drug in question was belrestotug, its lead candidate in the clinic for… August 11, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email